TY - JOUR
T1 - Dupilumab therapy of atopic dermatitis of the elderly
T2 - a multi-centre, real-life study
AU - group, DADE - Dupilumab for Atopic Dermatitis of the Elderly study
AU - Patruno, C
AU - Napolitano, M
AU - Argenziano, G
AU - Peris, K
AU - Ortoncelli, M
AU - Girolomoni, G
AU - Offidani, A
AU - Ferrucci, S M
AU - Amoruso, G F
AU - Rossi, M
AU - Stingeni, L
AU - Malara, G
AU - Grieco, T
AU - Foti, C
AU - Gattoni, M
AU - Loi, C
AU - Iannone, M
AU - Talamonti, M
AU - Stinco, G
AU - Rongioletti, F
AU - Pigatto, P D
AU - Cristaudo, A
AU - Nettis, E
AU - Corazza, M
AU - Guarneri, F
AU - Amerio, P
AU - Esposito, M
AU - Belloni Fortina, A
AU - Potenza, C
AU - Fabbrocini, G
N1 - <p>This article is protected by copyright. All rights reserved.</p>
PY - 2020
Y1 - 2020
N2 - BACKGROUND: Treatment of moderate-to-severe atopic dermatitis in the elderly may be challenging, due to side effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab is not yet well known.OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥ 65 years and affected by severe AD. Their main clinical features were also examined.METHODS: Data of elderly patients with severe (EASI≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS, and DLQI) scores at baseline and after 16 weeks of treatment.RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis, The coexistence of more than 1 phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event.CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.
AB - BACKGROUND: Treatment of moderate-to-severe atopic dermatitis in the elderly may be challenging, due to side effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab is not yet well known.OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥ 65 years and affected by severe AD. Their main clinical features were also examined.METHODS: Data of elderly patients with severe (EASI≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS, and DLQI) scores at baseline and after 16 weeks of treatment.RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis, The coexistence of more than 1 phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event.CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.
U2 - 10.1111/jdv.17094
DO - 10.1111/jdv.17094
M3 - Article
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
SN - 0926-9959
ER -